Publications

pharmacology

Department of Pharmacology Started in 1992

Department Medicine

Dr. Rajiv Kumar
Sr No. Research activities
1. Dr.Rajiv Kumar, Dr.Jagjit Singh: RE: Higher Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability Is Associated With Lower Cognitive Performance, Lower Cerebral Blood Flow, and Greater White Matter Hyperintensity Load in Older Subjects. eLetters Published on July 29, 2016 Circulation AHA JOURNALS http://circ.ahajournals.org/content/134/3/212/tab-e-letters
2. Dr.Rajiv Kumar : Diabetogenic effect of statins is difficult to ignore. (e-letter to the editor ) Published 9 March 2016 BMJ Heart http://heart.bmj.com/content/102/3/198/ reply#heartjnl_el_19333
3. Dr.Rajiv Kumar, Dr.Jagjit Singh: “Notice of Retraction”- The patients and society. Comments (1) . Posted on July 2, 2016. JAMA Intern Med. https://archinte.jamanetwork.com/article.aspx?articleid=2526968 ( Notice of Retraction: Sato Y, et al. The Prevention of Hip Fracture With Risedronate and Ergocalciferol Plus Calcium Supplementation in Elderly Women With Alzheimer Disease: A Randomized Controlled Trial. Arch Intern Med. 2005;165(15):1737-1742. Howard Bauchner, MD; Rita F. Redberg, MD, MSc. JAMA Intern Med. Published online June 03, 2016. doi:10.1001/jamainternmed.2016.3177)
4. Dr. Rajiv Kumar, Dr.Jagjit Singh: Better evidence: For the benefits of public at large. Cite this as:BMJ 2016;353:i3483/rr-1 http://www.bmj.com/content /353/bmj. i3483/rr-1
5. Dr. Rajiv Kumar, Dr. Jagjit Singh: Re: Whole grain consumption and risk of cardiovascular disease, cancer, and all cause and cause specific mortality: systematic review and dose-response meta-analysis of prospective studies. Cite this as: BMJ 2016;353:i2716/rr-4 http://www.bmj.com/content/353/bmj.i2716/rr-4
6. Dr. Rajiv Kumar, Dr.Jagjit Singh: Significance of using RAS blockers remains unchanged. Cite this as: BMJ 2016;352:i438/rr-0 http://www.bmj.com/content/352 /bmj.i438/rr-0
7. Dr.Rajiv Kumar: Wearable Fitness Trackers must be standarized , must be user-friendly and must be eco-friendly. Comments(1) Posted on April 21, 2016. JAMA Cardiol. https://cardiology.jamanetwork.com/article.aspx?articleid=2513306#tab10 Article/ comments Fitness trackers. JAMA Cardiol. 2016;1(2):239. doi:10.1001/ jamacardio.2016.0354. May1,2016 comments published.
8. Dr.Rajiv Kumar, Dr.Jagjit Singh. RE: Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on Conduction System Disease.Comments (1).Posted on June 29, 2016.JAMA Intern Med http://archinte.jamanetwork.com/article.aspx?articleid=2530285 JAMA Intern Med. Published online June 27, 2016. doi:10.1001/jamainternmed.2016.2502
9. Doctors and medical students in India should stop wearing white coats: Is not the Right Solution Site this as: BMJ 2015;351:h3855/rr-3 http://www.bmj.com/content/351/bmj.h3855/rr-3
10. Selective clinical trial reporting - A threat to society. Cite this as: BMJ 2015;350:h2613/rr# http://www.bmj.com/content/350/bmj.h2613/rr#
11. Chronic fatigue syndrome (CFS): What is recent knowledge? Or same as in the past?. Cite this as: BMJ 2015;350:h2087/rr-8 http://www.bmj.com/content/350/bmj.h2087/rr-8
12. The question is how to minimize prolonged sitting and handle sedentary behavior? Cite this as: BMJ 2015;350:h2961/rr# http://www.bmj.com/content/350 /bmj.h2961/rr#
13. Jagjit Singh, Rajiv Kumar: Phentermine-Toplramate; First combination drug for obesity. Int J App Basic Med Res 2015; Vol 5 : 157-8.
14. Ranibizumab is not a safe treatment alternative for proliferative diabetic retinopathy Cite this as: BMJ 2015;351:h6145/rr http://www.bmj.com/content/ 351/bmj.h6145/rr
15. Is it rational to compare ibuprofen with fosfomycin? Relief of Symptoms and Cure of Infection are different aspects of treatment. Cite this as: BMJ 2015;351:h6544/rr http://www.bmj.com/content/351/bmj.h6544/rr
16. Re: The risk of fall and fracture with the initiation of a prostate-selective α antagonist: a population based cohort study .Cite this as: BMJ 2015;351:h5398/rr http://www.bmj.com/content/351/bmj.h5398/rr
17. To Study the Effect of Calcium & Vitamin D Alone in Patients of Osteoporosis : Not Justifiable and Not-ethical in Present Time. Cite this as: BMJ 2015;351:h4825/rr-2 http://www.bmj.com/content/351/bmj.h4825/rr-2
18. Re: Association between guideline recommended drugs and death in older adults with multiple chronic conditions: population based cohort study. Cite this as: BMJ 2015;351:h4984/rr/rr http://www.bmj.com/content/351/bmj.h4984/rr
19. Combination of factors play the role. Cite this as: BMJ 2015;351:h5000/rr-0 http://www.bmj.com/content/351/bmj.h5000/rr-0
20. Dr.Rajiv Kumar & Dr.Jagjit Singh: Electronic cigarettes.Cite this as: BMJ 2015;351:h4634/rr-0 http://www.bmj.com/content/351/bmj.h4634/rr-0
21. Working long hours is associated with higher risk of stroke: The Time Has Come to Manage Risk. Cite this as: BMJ 2015;351:h4523/rr http://www.bmj.com/content/351/bmj.h4523/rr
22. Saturated fats and Trans fats Consumption : No Clear Consistent and Conclusive Results in Health Risks. Cite this as: BMJ 2015;351:h3978/rr-4 http://www.bmj.com/content/351/bmj.h3978/rr-4
23. Consumption of spicy foods in moderation is beneficial. Cite this as: BMJ 2015;351:h3942/rr-2 http://www.bmj.com/content/351/bmj.h3942/rr-2
24. Mediterranean diet and therapeutic implications. (WriteClick®) http://www.neurology.org/content/85/20/1744/reply#neurology_el_64214 Re: "Mediterranean diet and brain structure in a multiethnic elderly cohort" Gu, et al doi:http://dx.doi.org/10.1212/WNL.0000000000002121 Published December 1, 2015
25. The time has come to stop evaluating effect of Calcium & Vitamin D alone in patients of osteoporosis. Posted by RajivKumar on 17 Oct 2015 at 06:17 GMT (Reader Comments ) PLOSONE http://www.plosone.org/article/comments/info:doi/10.1371/journal.pone.0128032
26. Habitual chocolate consumption and risk of cardiovascular disease among healthy men and women: Pre-determined research or/ "made-to-order" research ? (Letter to the editor ) http://heart.bmj.com/content/101/16/1279/reply#heartjnl_el_19268 Published 9 September 2015
27. Progression to Traditional Cigarette Smoking After Electronic Cigarette Use Among US Adolescents and Young Adults (Comments) Brian A et al. JAMA Pediatr. 2015;169(11):1018-1023. doi:10.1001/jamapediatrics.2015.1742. http://archpedi.jamanetwork.com/article.aspx?articleid=2436539
28. Vitamin D Status and Rates of Cognitive Decline in a Multiethnic Cohort of Older Adults (Comments) Joshua W et al. JAMA Neurol. 2015;72(11):1295-1303. doi:10.1001/jamaneurol.2015.2115. http://archneur.jamanetwork.com/article.aspx?articleid=2436596#tab10
29. Rajiv Kumar, Jagjit Singh. The Emerging Therapy with Probiotics in the Management of Inflammatory Bowel Disease-Current Status . Int J Basic Clin Pharmacol. 2013. Aug; 2(4): 360-367
30. Jagjit Singh, Rajiv Kumar. Recent changes in regulation of clinical trial in India:An update for investigators (Brief communication) published in the Journal of Medical College Chandigarh ; Vol 3, No 2, Sept 2013.
31. Jagjit Singh, Rajiv Kumar. India moves closer to regulating prices of patented drugs: BMJ 2014; 348: g1244 , (Letter to editor rr).
32. Jagjit Singh, Rajiv Kumar. Drug patents cause fresh spat between South Africa and Industry: BMJ 2014; 348: g1377 , (Letter to editor rr).
33. Rajiv Kumar, Jagjit Singh. Kumar R, Singh J. Biosimilar drugs: current status. Int J Appl Basic Med Res. 2014; 4(2): 63–66. http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC4137643/
34. Rajiv Kumar, Jagjit Singh Electronic cigarettes - Solution or A big problem. (Letter to editor rr). Cite this as: BMJ 2015;350:h2110/rr
35.  Rajiv Kumar, Jagjit Singh. Metformin Journey: Past, Present and Future.(Letter to editor rr). Cite this as: BMJ 2015;350:h454/rr
36. Rajiv Kumar, Jagjit Singh. Re: Doctors less likely than patients to report toxicity of cancer treatments, study shows (Letter to editor rr) Cite this as : BMJ 2015;350:h485/rr
37. Rajiv Kumar, Jagjit Singh. Re: E-cigarettes latest: users on the up but rules tighten. (Letter to editor rr). Cite this as: BMJ 2014;349:g6444/rr
38. Re: E-cigarettes: the best and the worst case scenarios for public health—an essay by Simon Chapman. (Letter to editor rr). Cite this as:BMJ 2014;349:g5512 /rr
39. Rajiv Kumar, Jagjit Singh. Re: Regulation of electronic cigarettes. (Letter to editor rr). Cite this as: BMJ 2014;349:g5484/rr
40. Rajiv Kumar, Jagjit Singh . Thirteen women die from mass sterilisation in Chhattisgarh. (Letter to editor rr). Cite this as: BMJ 2014;349:g6868/rr
41. Rajiv Kumar, Jagjit Singh.Re: First TV advertisement for e-cigarettes prompts complaints. (Letter to editor rr). Cite this as : BMJ 2014;349:g7100/rr
42. Rajiv Kumar, Jagjit Singh.Re: Children are three times as likely to try e-cigarettes as tobacco products, study finds. (Letter to editor rr). Cite this as: BMJ 2014;349:g7508/rr
43. Rajiv Kumar, Jagjit Singh. Re: Food and cancer risk- Add soy products, fruits and vegetables in diet. (Letter to editor rr). Cite this as: BMJ 2014;349:g7819/rr
44. Rajiv Kumar Re: Drug policy: we need brave politicians and open minds. (Letter to editor rr). Cite this as: BMJ 2014;349:g7603/rr
45. Rajiv Kumar Re: Yoga reduces cardiovascular risk as much as walking or cycling, study shows. (Letter to editor rr). Cite this as: BMJ 2014;349:g7713/rr
46. Jagjit Singh ,Rajiv Kumar. The changing scenario of clinical trials in India: What’s new in 2014. J Medical Coll Chandigarh 2014;4 (1): 15-16.
47. Jagjit Singh, Rajiv Kumar. Recent advances in drug therapy of hyperlipoprotene- mias. J Med Col Chandigarh. 2015; 5(1) 6-8.
48. Rajiv Kumar, C. S Gautom, Jagjit Singh: Paper entitled “ The Old Concept With A New Attitude: Synbiotics Current Status ”, Presented in the South East Asia Regional Public Health Conference & 57th All India Conference of IPHA , held at Science City Kolkata on 1st -3rd Feb 2013, and abstract published in souvenir of IPHACON 2013 .
49. Attended, 2nd International and 5th National Conference of Indian Society for Rational Pharmacotherapeutics “ISRPTCON 2013”, held at DMCH Ludhiana on 30th -1st Feb 2014, and presented paper entitled “The Emering role of vitamin D: Current status”.
50. Attended IPS North Zone Conference held at GLA University Mathura on Feb 15-16,2014, & presented paper entitled “The Pleotropic Effect of vitamin D”.
51. Jagjit singh, Rajiv Kumar, Abstract of the paper entitled “Current status of drug therapy in management of Obesity”, Published in Indian Journal of Pharmacology: Dec 2013, Vol 45, Suppl S165.
52. Attended, 4th Biennial Conference of Gastrointestinal Infection Society of India “GISICON 2014” , held at GMCH Sector 32 Chandigarh on 11-12th April 2014, and presented paper entitled “New drugs in development for Hepatitis C".
53. Rajiv Kumar, Jagjit singh : presented paper entitled “Electronic Nicotine Delivery System & Safety issues; Current Status” SOPICON 2014 at JNMC, AMU, Aligarh December 1-3rd 2014 & Abstract of the paper published in Journal of Pharmacovigilance & Drug Safety, Volume 11, No. 5; 2014 (Conference Suppliment Issue)
54. Jagjit Singh, Rajiv Kumar . “Elderly population and potentially inappropriate medication: An Indian perspective”. p 32 Abstract published in the proceedings of 5th Annual conference of of Society of Biological Scientists of India. Sri Guru Ramdas Institute of Medical Sciences and Research, Sri Amritsar. 26th -28th Nov.2015.
55. Rajiv Kumar: Participated in “CME on Haemovigilance For Clinicians”, held on 26th April 2014, GMCH 32 Chandigarh.
56. ‘Hands-On’ Capacity Building CReATE workshop for Ethics Committees at GMCH & PGIMER, Chandigarh, 9th -11th October , 2015 .
57. Chaired a Scientific Session in “ISRPTCON 2015”, held at PGIMER Chandigarh on 4-6 DEC 2015.
58. Bhanwra S, Kumar R, Garg G. Introduction of a teaching module on intravenous drug administration and communication skills in pharmacology. Int J Basic Clin Pharmacol 2019;8:1825-9. http://dx.doi.org/10.18203/2319-2003.ijbcp20193185 .
59. Singh J, Singh H, Rohilla R, Kumar R, Gautam CS. Lack of awareness of pharmacovigilance among young health-care professionals in India: An issue requiring urgent intervention. Int J App Basic Med Res 2018;8:158-63.
60. Bhanwra S, Kumar R, Mahajan SS. Why do we need to think twice before prescribing Fluoroquinolones? JMCC 2019 ; 9(1) : 31-3.
  e-Letters/ comments.
1. (NEJM, Annals of Internal Medicine, JAMA Internal Medicine and BMJ )   PLOS I Medicine-Reader Comments: Rajiv Kumar. The time has come to adopt a risk-based approach to lower CVD risk in managing high BP 05 Apr 2018 http://journals.plos.org/plosmedicine/article/comment?id=10.1371/annotation/a8c5a261-b22e-444b-954a-2a8ab72cd5cc .
2. MSA is a very good initiative & need of the time, to save lives of peoples. Comments-Rajiv Kumar, September 19,2018. N Engl J Med 2018; 379:997-1000 https://www.nejm.org/doi/full/10.1056/NEJMp1802633#article_comments .
3. ASPREE TRIAL: Preventive Use of Aspirin in Elderly, Ends the Confusion. Comments-RajivKumarSeptember22,2018. N Engl J Med 2018; 379:1499-1508 https://www.nejm.org/doi/full/10.1056/NEJMoa1800722#article_comments.
4. ENDS, and 'Turning life to End'. Comments- Rajiv Kumar September 26, 2018. N Engl J Med 2018; 379:1099-1102 https://www.nejm.org/doi/full/10.1056/NEJMp1805758#article_comments.
5. RE: Pantoprazole in Patients at Risk for GIT Bleeding in the ICU. COMMENTS Rajiv Kumar Oct 31, 2018 N Engl J Med 2018; 379:2199-2208.
6. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa RE: It is very early to reach final conclusion. COMMENTS Rajiv Kumar Jan 16, 2019 N Engl J Med 2019; 380:121-131 https://www.nejm.org/doi/full/10.1056/NEJMoa1813598#article_comments
7. American College of Physicians Ethics Manual: Seventh Edition COMMENTS : Seventh Edition of ACP’s Ethics Manual is very informative and will bepractical guide to other countries Dr.Rajiv Kumar January 22, 2019 Annals of Internal Medicine http://annals.org/aim/fullarticle/2720883/american-college-physicians-ethics-manual-seventh-edition
8. No Shortcuts to Safer Opioid Prescribing. RE: Rational and Safe Use of Opioids. COMMENTS Rajiv Kumar June 19, 2019 N Engl J Med 2019; 380:2285-2287 DOI: 10.1056/NEJMp1904190
9. Chances of Mixed Infection COMMENTS Rajiv Kumar Case 19-2019: A 38-Year-Old Woman with Abdominal Pain and Fever June 20, 2019 N Engl J Med 2019; 380:2461-2470 DOI: 10.1056/NEJMcpc1900594
10. RE: Electrocardiographic Changes After Overdose of Epinephrine in a Patient With Anaphylaxis. JAMA Internal Medicine Comments Rajiv Kumar July16, 2019 JAMA Intern Med. 2019;179 (7):973-974 https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2732685
11. RE: Assessment of Self-reported Prognostic Expectations of People Undergoing Dialysis. JAMA Internal Medicine Comments Rajiv Kumar July 19, 2019 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2737752
12. RE: Association Between Electronic Cigarette Use and Smoking Reduction. JAMA Internal Medicine Comments Rajiv Kumar July 24, 2019 https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2737916
13. RE: Acupuncture as Adjunctive Therapy for Chronic Stable Angina A Randomized Clinical Trial. JAMA Internal Medicine Comments Rajiv Kumar August 5, 2019 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2739058
14. Dr. Rajiv Kumar, Gaurav Garg Re: Reducing anaemia in low income countries: control of infection is essential, BMJ 2018;362:k3165/rr 02 August 2018 https://www.bmj.com/content/362/bmj.k3165/rr
15. Dr.Rajiv Kumar, Dr.Sangeeta RE: Alcohol consumption, dementia and truth ?.BMJ 2018;362:k2927 /rr-5 11 August 2018 https://www.bmj.com/content/362/bmj.k2927/rr-5
16. Dr.Rajiv Kumar Re: Diclofenac use and cardiovascular risks: series of nationwide cohort studies BMJ 2018;362:k3426/rr-2 10 September 2018 https://www.bmj.com/content/362/bmj.k3426/rr-2
17. Dr.Rajiv Kumar Re: Alcohol must be recognised as a drug BMJ 2018;362:k3944/rr-2 24 September 2018 https://www.bmj.com/content/362/bmj.k3944/rr-2
18. Dr. Rajiv Kumar, Dr. Sangeeta Bhanwara Re: Evaluation of the causal effects between subjective wellbeing and cardiometabolic health: mendelian randomisation study BMJ 2018;362:k3788/rr 02 October 2018 https://www.bmj.com/content/362/bmj.k3788/rr
19. Dr. Rajiv Kumar, Dr. Sangeeta Bhanwara Re: Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors BMJ 2018;363:k3654/rr 04 October 2018 https://www.bmj.com/content/363/bmj.k3654/rr
20. Dr. Rajiv Kumar Re: Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study BMJ 2018;363:k4209/rr-5 27 October 2018 https://www.bmj.com/content/363/bmj.k4209/rr-5
21. Dr. Rajiv Kumar Re: Shift Work Sleep Disorder (SWSD), and Known Health Risk BMJ 2018;363:k4641/rr-1 28 November 2018 https://www.bmj.com/content/363/bmj.k4641/rr-1
22. Dr. Rajiv Kumar Re: The Materiovigilance Programme Of India (MvPI). Cite this as: BMJ 2018;363:k5032/rr-0 30 November 2018 https://www.bmj.com/content/363/bmj.k5032/rr-0
23. Dr. Rajiv Kumar Re: Mnemonic MA-ESR or " MARSE". BMJ 2018;363:k4766/rr 05 December 2018 https://www.bmj.com/content/363/bmj.k4766/rr
24. Dr. Rajiv Kumar, Dr. Sangeeta Bhanwara. Re: Judicious and responsible use of MSCT scanners. BMJ 2019;364:k4931/rr-1 14 January 2019 https://www.bmj.com/content/364/bmj.k4931/rr-1
25.  Dr. Rajiv Kumar, Dr. Sangeeta Bhanwara, Dr.Sonia Shinde, Jtin Sharma Re: Association of fried food consumption with all cause, cardiovascular, and cancer mortality: prospective cohort study, BMJ 2019;364:k5420/rr-1 , 31 January 2019 https://www.bmj.com/content/364/bmj.k5420/rr-1
Sr No. Award /Fellowship
1. Awarded fellowship of International Medical Science Academy, FIMSA.
Dr. Sangeeta Bhanwra
Sr No. Research activities
1. Bhanwra S, Kumar R, Garg G. Introduction of a teaching module on intravenous drug administration and communication skills in pharmacology. Int J Basic & clinical Pharma 2019 ; 8(8): 1825-29.
2. Bhanwra S, Kumar R, Mahajan SS. Why do we need to think twice before prescribing fluoroquinolones? JMCC 2019; 9(1):31-33.
3. Bhanwra S, Kumar R. Re : Use of hormone replacement therapy and risk of venous thrombo-embolism: nested case-control studies using the QResearch and CPRD databases. HRT: Are Route and Type of Oestrogen important to consider? BMJ 2019;364:k4810/rapid-responses.
4. Kumar R, Bhanwra S, Mahajan SS, Sharma J. Re : Association of fried food consumption with all cause, cardiovascular, and cancer mortality: prospective cohort study. BMJ 2019;364:k5420/ rapid responses.
5. Kumar R, Bhanwra S. Re: International variation in radiation dose for computed tomography examinations: prospective cohort study. BMJ 2019; 364: k4931/rapid responses.
6. Sangeeta Bhanwra, Kaza Ahluwalia . Empagliflozin: the latest SGLT2 inhibitor on the block. Int J Basic Clin Pharmacol 2016; 5(2): 539-542
7. Bhanwra S, Ahluwalia K, The association of oral contraceptive pills with increase in intraocular pressure; Time for pharmacovigilance to step in. J Pharmacol Pharmacother 2015; 6(1): 51-52
8. Bhanwra S, Ahluwalia K. A novel approach in the treatment of rheumatoid arthritis: Janus Kinase inhibitors. Int. J Basic & clinical Pharma 2015;4 (3) : 598-600. 5(4): 275
9. Bhanwra S, Ahluwalia K. Recently reemerging viral infections in India; A brief overview. Journal of IPHA Chandigarh State branch. Vol. 3 & 4 (July 14 & 15)
10. Bhanwra S, Ahluwalia K. Methicillin resistant staphylococcus aureus: New avenues for treatment. J Medical College Chandigarh 2014;4(2):7-9.
11. Liraglutide in diabetes: making a new place. http://www.bmj.com/content/351/bmj.h5364/rr-0 
12. Newer oral anticoagulants gradually establishing their mettle.http://www.bmj.com/content/351/bmj.h5876/rr
13. How safe are the newer “safe” anticoagulants ? Re: Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. http://www.bmj.com/content/350/bmj.h1585/rr-0
14. Bhanwra S, Ahluwalia K, Acetaminophen associated with risk of hearing loss; A safety alert. J Pharmacol Pharmacother 2014; 5(4): 275.
15. Bhanwra S, Ahluwalia K. Author reply. J Pharmacol Pharmacother 2014; 5:169.
16. Kaza Ahluwalia, Sangeeta Bhanwra. Antiplatelet therapy: present status and its future directions. Int J Basic Clin Pharmacol. 2014; 3(2): 260-268.
17. Sangeeta Bhanwra, Kaza Ahluwalia. The New factor Xa inhibitor : Apixaban. J Pharmacol and Pharmacother 2014;5:12-14.
18. Bhanwra S, Ahluwalia K. A novel treatment for Type2 diabetes mellitus: Canagliflozin. Int J Pharmacol and Clin Sci 2013;2:129-34.
19. Sangeeta Bhanwra, Kaza Ahluwalia. Re: Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. http://www.bmj.com/content/347/bmj.f5133/rr/661862
20. Sangeeta Bhanwra, Kaza Ahluwalia. Re: Flouting evidence in a rush to the market: do we know enough about the drugs we prescribe? Need of the hour: Refreshing the outlook & discovering newer alternatives. http://www.bmj.com/content/347/bmj.f4528/rr/655304
21. Kaza Ahluwalia,Sangeeta Bhanwra.To study the clinical uses and associated risks of type 1 Protease Activated Receptor Antagonists. Int J Basic & Applied Medical Sciences. Jan-April 2013.
22. Sangeeta Bhanwra, Kaza Ahluwalia, Kavita Sekhri. Revacept: Collagen GP VI receptor inhibitor, a new & a formidable target for antiplatelet action. Int J Basic & Clinical Pharmacology June 2013.
23. Sangeeta Bhanwra. A study of non-prescription usage of antibiotics in the upper respiratory tract infections in the urban population. J Pharmacol Pharmacother2013;4(1):62-4.
24. Kavita Sekhri, Sangeeta Bhanwra, Ruchika Nandha. Herbal Products : a survey of students’ perception and knowledge about their medicinal use.Int J Basic & Clinical Pharmacology 2013;2(1):71-6.
25. Sangeeta Bhanwra. Extensively Drug Resistant Tuberculosis: An Upcoming Challenge to Face and Threat. Int J Pharma & Biosciences 2012; 3(2):124-27.
26. Sangeeta Bhanwra. To Study the benefits and Challenges involved in the use of polypill prophylactically for the cardiovascular diseases. Int J Basic & Applied Medical Sciences.2012; 2(1).71-3.
27. Sangeeta Bhanwra. Management of Allergic Rhinitis. Int J Pharma & Biosciences 2010; 2(1)2011:261-6.
28. Sangeeta Bhanwra. Post menopausal Hormone Replacement Therapy – A Review. Int J Pharma & Biosciences 2010;1(2):1-8.
29. Gautam CS, Bhanwra S. Neglected tropical diseases : need for sensitization of medical students. Indian J Pharmacol 2008 ; 40(3) :132-3.
30. Gautam CS, Bhanwra Sangeeta. Pharmacoeconomics:sensitization of undergraduate medical students. Indian J Pharmacol 2005;37(5):336.
31. Gautam CS, Bhanwra Sangeeta, Goel NK. Effect of captopril on pain perception in rats. Indian J Pharmacol 2003;35:59-60.
32. Bhanwra Sangeeta, Kaushal Jyoti, P Khosla, Bose S. Status of leukotriene antagonists in bronchial asthma. Drugs: News and Views 2001;6(1):12-5.
33. Gautam CS, Bhanwra Sangeeta, Goel NK, Gupta SK, Sood S. Instillation of drugs in eye: Importance of proper instructions to patients. Indian J Pharmacol 2001;33(5):386.
34. Jhaj R, Goel NK, Gautam CS, Hota D, Bhanwra Sangeeta, Sood S, Sachdev A. Prescribing pattern and cost of antihypertensive drugs in an internal medicine clinic.Indian Heart J 2001;53:323-7.
35. Bhanwra S, Gautam CS, Goel NK. Tuberculosis-Approach in 21st century.CMJ2000,VI(6):35-41.
36. Bhanwra S, Sangwan S, Goel NK. Management of glaucoma: An overview. HMJ 2000;20(7);10-3
37. Bhanwra S, Goel NK. Management of Rheumatoid arthritis-current status of drugs used.CMJ 2000;V(10):13-7.
38. Khosla P, Bhanwra Sangeeta, Singh J, Srivastava RK. Antinociceptive activity of Azadirachta Indica (Neem)in rats. Indian J Pharmacol 2000;32(6):372-4.
39. Khosla P, Bhanwra Sangeeta, Singh J,Srivastava RK. Astudy of hypoglycemic effects of Azadirachta Indica (neem) in normal and alloxan diabetic rabbits. Indian J Physiol Pharmacol 2000;44(1):69-74.
40. Bhanwra Sangeeta, Singh J, Khosla P. Effect of leaf extract on Paracetamol induced liver damage in rats . Indian J Physiol Pharmacol 2000;44(1):64-8 .
41. Khosla P, Bhanwra S, Kaushal J. Management of gastro-esophageal reflux disease. HMJ 1999; 20(1-2):3-4.
42. Khosla P, Bhanwra S, Kaushal J. Antioxidants : Current Status. HMJ 1999;19 (11-12) ;12-3.
Sr No. Awards/Academic Achievements
1. Awarded Fellowship of International Medical Science Academy FIMSA
2. Awarded membership of National Academy of Medical Sciences (MAMS).
3. Life Memberships :
- Indian Pharmacological Society (IPS)
-  Association of Physiologists & Pharmacologists of India (APPI)
- International Society of Rational Pharmacotherapeutics (ISRPT)
- National Academy of Medical Sciences
- Indian Medical Association (IMA)
- Indian Public Health Association (IPHA)
- Indian Society of Pharmacovigilance
4. Member of Editorial Boards of journals :
- International Journal of Basic and Clinical Pharmacology
- Journal of Medical College Chandigarh
5. Reviewer of Journals:
- Indian Journal of Pharmacology (since 2002)
- Journal of Pharmacology and Pharmaco-therapeutics
- International Journal of Basic and Clinical Pharmacology
Sr No. Conferences, CMEs & Workshops Attended
1. Acted as a Judge in the poster session in ‘ISRPTCON 2015. 7th National Conference of Indian Society of Rational Pharmacotherapeutics from December 4- 6th, 2015 at PGIMER, Chandigarh.
2. Attended ‘Adolescent and Youth friendly Health Initiative (AYFHI) through Mentoring programs for students’from August 27-28, 2015, organized by Deptt. Of Community Medicine, GMCH, Chandigarh.
3. Attended 70th Annual Conference of The association of Physicians of India (APICON) from feb 19-22nd, 2015 at Gurgaon and presented a paper entitled Schedule H1 : A novel weapon in the existing arsenal of fighting antibiotic resistance’.
4.  Attended 14th Annual Conference of Society of Pharmacovigilance, India from Dec 1-3, 2014 at JNMU, AMU, Aligarh, UP and presented a paper entitled ‘Role of pharmaco-vigilance in the newly found controversy of oral contraceptive pills and intraocular pressure changes.
5. CME on Haemovigilance for clinicians, organised by department of transfusion medicine, GMCH, Chandigarh & Pharmacovigilance Centre &Regional Resource Centre , PGIMER, Chandigarh, on April 26th,2014.
6.  Attended ISRPTCON 2013. 2nd International and 5th National Conference of Indian Society for Rational Therapeutics; Organised by Department of Pharmacology, Dayanand Medical College Medical, Ludhiana, Panjab & presented a paper entitle “ Regular use of acetaminophen associated with risk of hearing loss”.
7.  Attended 11th Annual Conference of International Society for Heart Research (Indian Section) Organised by Department of Pharmacology & Toxicology NIPER, S.A.S. Nagar, Panjab on Feb 8-9, 2014 & presented a Paper entitled ‘Apixaban: A recent addition to the therapy of thromboembolic disorders’.
8. 4th Training programme for Technical Associates of North Zone under Pharmacovigilance programme of India organised by PGIMER, Chandigarh on December 21, 2013.
9.  Participated as a faculty and delivered a lecture on the topic” Pharmacological management of pain” in Workshop on Pain Education in graduate medical school in India organised by Deptt. Of Anaesthesia, GMCH, Chandigarh on December 14, 2013.
10. Attended Woundcon 2013;XVI Annual Conference of Indian Society of Wound management organised by Department of Surgery, Government Medical College & Hospital, Chandigarh on Nov.23 & 24, Presented a Paper entitled “To study the current status of pharmacological management of venous thrombo-embolic disorders”.
11. CME on diagnostic challenges in lab medicine Organised by Department Of Biochemistry, GMCH, Chandigarh on November 14, 2013.
12. CME on “Matters of the Heart” organized by Indian Medical Association on Oct. 27, 2013.
13. Resource faculty in workshop on Randomized Response Techniques for Sensitive Surveys on October 20, 2012 at GMCH, Chandigarh.
14. 31st Annual National Workshop on Clinical Pharmacology & Therapeutics (NWCPT-2013) March 11th to 15th 2013, at PGIMER, Chandigarh.
15. Workshop on recent advances in prenatal and neonatal screening by genetic centre, GMCH, Chandigarh on May 11, 2012.
16. Basic Course Workshop in Medical Education Technologies; 29-31st March, 2012 at CMC, Ludhiana.
17. MEU Coordinators’ Workshop in Medical Education Technologies; 28th March 2012 at CMC, Ludhiana.
18. Workshop on ICD 10 coding organized by CBHI, Govt of India on March 16, 2012 at GMCH, Chandigarh.
19. CME on “Pharmacovigilance : a Primer” by Department of Pharmacology Pt.BDS PGIMS, Rohtak on March 20th, 2010.
20. Participated as Joint Secretary in the CME 2010 - on “Obesity - A Growing Challenge” organized by Deptt. of Pharmacology & Dietetics, at Government Medical College & Hospital, Chandigarh, on 29 th January 2010.

Dr. Jagjit Singh

Sr No. Research activities
1. Singh H, Rao SV, Kakkar AK, Singh J, Manohar HD. Posttrial access to medical interventions: Intricacies, challenges, and solutions. Intervention. Int J App Basic Med Res. 2019 Jan-Mar; 9(1): 3–8. (review article)
2. MPK, Patil A, Kakkar AK, Singh H. Decoding the Roadmap for Capacity Building of Pharmacology Academicians in Catering to Drug Information Center Services in a Developing Country. Journal of Pharmacy Technology, 2019;35(4), 146–154. 37. (research article)
3. Gautam CS, Mahajan SS, Sharma J, Singh H, Singh J. Repurposing potential of ketamine: Opportunities and challenges. Accepted for publication in Indian J Psychol Med 2019.(review article, corresponding author)
4. Serum Vitamin D and Low Density Lipoprotein-Cholesterol Levels Do Not Predict the Occurrence of Statin Associated Muscle Symptoms. Research paper submitted to Int J App Basic Med Res (corresponding author).
5. Romosozumab: A Brief Overview of Its Pharmacology, Efficacy and Safety in Postmenopausal Women With Osteoporosis. Review article submitted to Journal of Medical College Chandigarh (review article, corresponding author).
6. Singh J, Singh H, Rohilla R, Kumar R, Gautam CS. Lack of awareness of pharmacovigilance among young health-care professionals in India: An issue requiring urgent intervention. Int J App Basic Med Res 2018;8:158-63.
7. Rajiv Kumar, Jagjit Singh. JAMA Intern Med. 2016; doi 10.1001/ jamainternmed. 2016.3177. (Published online July 2, 2016)
8. Rajiv Kumar, Jagjit Singh. Response to : Effect of Antihypertensive and Lipid –Lowering Treatment tp Prevent Heart Attack Trial (ALLHAT ) on Conduction System Disease. JAMA Intern Med.2016; doi 10.1001/jamainternmed.2016.2502 (Published online 27 June, 2016)
9. Rajiv Kumar, Jagjit Singh . Doctors less likely than patients to report toxicity of cancer treatments, study shows. BMJ 2015; 350 doi: http://dx.doi.org/ 10.1136/bmj. h485 (Published 28 January 2015)Cite this as: BMJ 2015;350:h485
10. Rajiv Kumar, Jagjit Singh . Fuming about e-cigarettes and harm. BMJ 2015; 351 doi: http://dx.doi.org/10.1136/bmj.h4634 (Published 26 August 2015)Cite this as: BMJ 2015;351:h4634
11. Rajiv Kumar, Jagjit Singh . Consumption of spicy foods and total and cause specific mortality: population based cohort study . BMJ 2015; 351 doi: http://dx. doi.org /10.1136/bmj.h3942 (Published 04 August 2015)Cite this as: BMJ 2015; 351: h3942
12. Rajiv Kumar, Jagjit Singh .The long wait for a breakthrough in chronic fatigue syndrome. BMJ 2015; 350 doi: http://dx.doi.org/10.1136/bmj.h2087 (Published 05 May 2015)Cite this as: BMJ 2015;350:h2087
13. Rajiv Kumar, Jagjit Singh .Working long hours is associated with higher risk of stroke, study shows. BMJ 2015; 351 doi: http://dx.doi.org/10.1136/bmj.h4523 (Published 20 August 2015)Cite this as: BMJ 2015;351:h4523
14. Rajiv Kumar, Jagjit Singh .Calcium supplements do not prevent fractures. BMJ 2015; 351 doi: http://dx.doi.org/10.1136/bmj.h4825 (Published 29 September 2015)Cite this as: BMJ 2015;351:h4825
15.  Rajiv Kumar, Jagjit Singh .Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. BMJ 2015; 351 doi: http://dx.doi.org/10.1136/bmj.h3978 (Published 12 August 2015)Cite this as: BMJ 2015;351:h3978
16. Rajiv Kumar, Jagjit Singh.Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program. BMJ 2015; 350 doi: http://dx.doi.org/10.1136/bmj.h454 (Published 19 February 2015)Cite this as: BMJ 2015;350:h454
17. Rajiv Kumar, Jagjit Singh . Teenagers, smoking, and vaping. BMJ 2015; 350 doi: http://dx.doi.org/10.1136/bmj.h2110 (Published 21 April 2015)Cite this as: BMJ 2015;350:h2110
18. Jagjit Singh. Many fixed dose drug combinations for sale in India are not approved. BMJ 2015; 350 doi: http://dx.doi.org/10.1136/bmj.h2517 (Published 13 May 2015)Cite this as: BMJ 2015;350:h2517
19. Jagjit Singh, Rajiv Kumar. Recent advances in drug therapy of hyperlipoprotenemias. J Med Col Chandigarh. 2015; 5(1)6-8
20. Singh Jagjit, Kumar Rajiv. Phentermine –topiramate : First combination drug for obesity. Int J App Basic Med Res 2015,5: 167-8.
21. Jagjit Singh, Rajiv Kumar. The changing scenario of clinical trials in India: What’s new in 2014. J Med Col Chandigarh. 2014; 4(1):15-16.
22. Rajiv Kumar, Jagjit Singh. Biosimilar drugs: Current Status. Int J App Basic Med Res 2014; 63-6.
23. Jagjit Singh. Anti-obesity drugs of the twenty-first century : Hope or hype.J Res Med Edu Ethics.014; 4(1) 1-2.
24. Jagjit Singh . Declaration of transparency for each research article. BMJ 2013; 347 doi: http://dx.doi.org/10.1136/bmj.f4796 (Published 07 August 2013)Cite this as: BMJ 2013;347:f4796
25. Jagjit Singh , Rajiv Kumar .Doctors in the private sector should report adverse events after immunisation to complete dataset. BMJ 2013; 347 doi: http://dx.doi. org/10.1136/bmj.f4968 (Published 07 August 2013)Cite this as: BMJ 2013;347:f4968
26. Jagjit Singh , Rajiv Kumar. India signals crackdown on dubious fixed dose drug combinations. BMJ 2013; 347 doi: http://dx.doi.org/10.1136/bmj.f4588 (Published 17 July 2013)Cite this as: BMJ 2013;347:f4588.
27. Jagjit Singh .Corruption: medicine’s dirty open secret. BMJ 2014; 348 doi: http://dx.doi. org /10.1136 /bmj.g4184 (Published 25 June 2014)Cite this as: BMJ 2014;348:g4184
28. Jagjit Singh, Bhargav Purohit, Anupama Desai, Lalita Savardekar, Preeti Shanbag, and Nilima Kshirsagar. Clinical Manifestations, Treatment, and Outcome of Hospitalized Patients with Plasmodium vivax Malaria in Two Indian States: A Retrospective Study. Malaria Research and Treatment. 2013.http://dx.doi.org/10. 1155/2013/341862
29. Kumar R, Singh J. The emerging therapy with probiotics in the management of inflammatory bowel disease: current status. Int J Basic Clin Pharmacol 2013; 2:360-7.
30. Jagjit Singh, Rajiv Kumar. Current status of drug therapy in management of obesity . Indian J Pharmacol 2013;45 (Supplement) S-165.
31. Jagjit Singh, Rajiv Kumar . Recent changes in regulation of clinical trials in India: an update for Investigators. J Med. Col Chandigarh. 2013; 3(2):21-23.
32. Jagjit Singh. Lorcaserin : A new drug for obesity. J Med Col Chandigarh. 2013; 3(1):42-44.
27. Jagjit Singh. Role of pharmacologists in clinical research: The onus is on us. Persp. Clin Res. 2013;2:154.
Sr No. Invited lectures
1. Drugs and the elderly: An update on clinical and policy perspectives. Guest lacture delivered at the 5th Annual Conference of Society of Biological Scientists of India. Sri Guru Ramdas Institute of Medical Sciences and Research, Sri Amritsar. 26th -28th Nov.2015.
2. “Introduction to Systematic Reviews” at the Workshop on Principles and Practice of Evidence- Based Healthcare,7-9th Dec 2012, GMCH, Chandigarh
3. “Understanding systematic reviews” at the Workshop on Evidence- Based Decision –making, 8-10th March 2013, GMCH, Chandigarh
Sr No. Awards and Honours
1. Delivered an invited Lecture on “ Drug use in Elderly : Linking Physiology and Pharmacology” at the VIIth Congress of Federation of Indian Physiological societies 27-29th September 2019, ESIC Medical College , Faridabad.
2. Member of Organising Committee : Hands-On’ Capacity Building CReATE workshop for Ethics Committees at Government Medical College and Hospital & PGIMER, Chandigarh, 9th -11th October , 2015 .
3. Best paper presentation award for the paper “Geographic variation in the clinical manifestations , treatment and outcomes of P.vivax malaria” of ICMR workshop on Outcomes Research at the Sixth International Annual Conference of South Asian Chapter of American College of Clinical Pharmacology, 21st -22nd April 2013, Mumbai.

 

Dr. Harmanjit Singh

Sr No.

PUBLICATIONS
1. Singh H, Thangaraju P, Chakrabarti A. Acinetobacter baumannii: A Brief Account of Mechanisms of Multidrug Resistance and Current and Future Therapeutic Management. Journal of Clinical and Diagnostic Research. 2013;7(11): 2602-2605.
2. Balasubramanian D, Singh H, Thangaraju P, Subramanian S, Natt NK. Cardiac Arrest. Uncommon Toxicity in Hair Dye Poisoning. J Rational Pharmacother Res 2013; 1(1):72-74
3.

Thangaraju P, Singh H, Chakrabarti A. Treatment of deep and superficial infections of Candida-What we know and what is new? Int J Pharm Sci Res 2013: 4(7); 2562-2568.
4. Thangaraju P, Singh H, Chakrabarti A. Antiplatelet Therapy and Resistance: A Mini Review. Int J Pharm Sci Res 2013; 4(11): 4090-97.
5. Natt NK, Singh T, Singh H, Sharma M, Singh G. Phenobarbitone induced drug reaction with eosinophilia and systemic symptoms (DRESS): a case report. Int J Basic Clin Pharmacol 2013;2:333-5
6.

Thangaraju P, Singh H , Dibyajyoti Banerjee D, Thangaraju E. Beneficial Effect of Lard in Androgenic Alopecia. J Rational Pharmacother Res 2013; 1(3):144-146
7. Singh H, Natt NK, Garewal N, Pugazhenthan T. Bedaquiline: a new weapon against MDR and XDR-TB. Int J Basic Clin Pharmacol 2013;2:96-102.
8. Singh J, Sehgal V, Singh H. Recent and Emerging trends in Pharmacotherapy of Neuropathic Pain. Int J Med and Dent Sci 2013; 2(1):45-58.
9. Singh H. Gill BS, Bajaj VK, Gupta A. An Open Prospective, Randomized Controlled Study to Evaluate the Antianginal Effect of Atorvastatin in Patients of Coronary Artery Disease with Dyslipidemia. J. Pharm. Sci. & Res. 2013;5(3):72 – 75.
10. Singh H, Arora E, Thangaraju  P, Medhi B. Enzalutamide as Promising Therapy in Castrate Resistant Prostate Cancer. JK Science; 2013;15 (2): 105-107.
11. Singh H, Kumar H, Thangaraju  P, Medhi B. Tafluprost: Adding New Dimension to Antiglaucoma Therapy. JK Science; 2013;15 (3): 159-162.
12. Singh H, Arora E, Thangaraju  P, Singh J, Natt NK. Antimicrobial Resistance: New Patterns, Emerging Concepts and Prevention. Rational Pharmacother Res 2013; 1(2): 95-99.
13. Singh H, Goyal M, Singh J, Arora E, Natt NK. Current and Emerging Trends in Pharmacological Management of Osteoporosis. Int. J. Pharm. Sci. Rev. Res. 2013;21(2): 143-147
14. Singh H, Thangaraju P, Kumar S, Aravindan U, Balasubramanian H, Selvan T. Knowledge and Awareness of Diabetes and Diabetic Ketoacidosis (DKA) Among Medical Students in a Tertiary Teaching Hospital: An Observational Study. J Clin Diagn Res. 2014;8(4):HC04-6.
15.

Kumar S, Singh H, Sharma J. Effect of lamotrigine, levetiracetam and phenytoin on learning and memory in albino rats. Int J Med and Dent Sci 2014; 3(2):388-395.
16.

Bhatia HK, Singh H, Grewal N, Natt NK. Sofosbuvir: A novel treatment option for chronic hepatitis C infection. J Pharmacol Pharmacother 2014;5:278-84. Cited by 100 ‎Related articles
17. Natt NK, Nagpal M, Chawla N, Singh T, Deepika, Singh H. Prevalence, patterns, characteristics and challenges in management of multi-drug resistant tuberculosis cases under DOTS-PLUS. Indian J Tuberc. 2014;61(3):207-12.
18. Pugazhenthan T, Singh H, Kumar P, Hariharan B. Is dysguesia going to be a rare or a common side-effect of amlodipine? Ann Med Health Sci Res 2014;4:43-4.
19. Singh T, Natt NK, Sharma M, Singh H. Congenital tuberculosis complicated by interstitial pulmonary emphysema. J Clin Neonatol 2014;3:41-3.
20. Singh H, Thangaraju P, Natt NK. Sleep-walking a rarest side effect of zolpidem. Indian J Psychol Med 2015;37:105-6.
21. Sharma A, Arora E, Singh H. Hypersensitivity reaction with deferasirox. J Pharmacol Pharmacother 2015;6:105- 6.
22. Thangaraju P, Singh H, Chakrabarti A. Regorafenib: A novel tyrosine kinase inhibitor: A brief review of its therapeutic potential in the treatment of metastatic colorectal carcinoma and advanced gastrointestinal stromal tumors. Indian J Cancer 2015;52:257-60.
23. Arora E, Singh H, Gupta YK. Impact of antiepileptic drugs on bone health: Need for monitoring, treatment, and prevention strategies. J Family Med Prim Care. 2016;5(2):248-253.
24. Kaushal S, Singh H, Thangaraju P, Singh J. Canagliflozin: A novel SGLT2 inhibitor for type 2 diabetes mellitus. North Am J Med Sci 2014;6:107-13.
25 Singh H, Mohan P, Kumar R, Gupta YK. Difference in described indications of medicines among drug information sources in India: An issue urgently to be addressed. J Nat Sci Biol Med. 2016;7(1):93-7.
26. Singh H, Ratol S, Thangaraju P, Kumar S, Goel A. Pharmacology and Anti-infective Role of Raxibacumab: A Novel Monoclonal Antibody for the Treatment of Anthrax. West Indian Med J. 2016 Feb 23;65(2):358-362.
27. Singh H, Grewal N, Arora E, Kumar H, Kakkar AK. Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med. 2016;7(1):4-9. ‎
28.

Singh H, Kaur M, Kakkar AK, Kumar H. The Promise of Dolutegravir: A Novel Second Generation Integrase Strand Transfer Inhibitor. Curr Clin Pharmacol. 2016;11(2):88-94.
29. Singh H, Chakrawarti A, Guruprasad P, Singh H, Gupta YK. Difference in occurrence of muscle-related adverse effects of statins among male and female geriatric patients: A cross-sectional observational study. Niger Postgrad Med J. 2016 Oct-Dec;23(4):202-208.
30. Goyal A, Singh H, Sehgal VK, Jayanthi CR, Munshi R, Bairy KL, et al. Impact of regulatory spin of pioglitazone on prescription of anti-diabetic drugs among physicians in India: A multicenter questionnaire based observational study. Indian J Med Res. 2017; 146(4): 468–475.
31. Singh H, Chakrawarti A, Singh H, Guruprasad P, Gupta YK. Evaluation of treatment satisfaction and efficacy and safety of dipeptidyl peptidase‑4 inhibitors in geriatric patients with type 2 diabetes mellitus: A cross‑sectional comparative study. J Family Med Prim Care 2018;7:70-6.
32 Singh H, Sarangi SC, Gupta YK. French Phase I clinical trial disaster: Issues, learning points, and potential safety measures. J Nat Sc Biol Med 2018;9:106-10.
33. Kakkar AK, Singh H, Medhi B. Old Wines in New Bottles: Repurposing Opportunities for Parkinson's Disease. Eur J Pharmacol. 2018 Jul 5;830:115-127.
34.

Singh J, Singh H, Rohilla R, Kumar R, Gautam CS.  Lack of Awareness of Pharmacovigilance Among Young Health Care Professionals in India: An Issue Requiring Urgent Intervention. Int J App Basic Med Res. 2018 Jul-Sep;8(3):158-163.
35. Singh H, Rao SV, Kakkar AK, Singh J, Manohar HD. Posttrial access to medical interventions: Intricacies, challenges, and solutions. Intervention. Int J App Basic Med Res. 2019 Jan-Mar; 9(1): 3–8.
36.

MPK, Patil A, Kakkar AK, Singh H. Decoding the Roadmap for Capacity Building of Pharmacology Academicians in Catering to Drug Information Center Services in a Developing Country. Journal of Pharmacy Technology, 2019;35(4), 146–154. 37.
37. Gautam C S, Mahajan SS, Sharma J, Singh H, Singh J. Repurposing potential of ketamine: Opportunities and challenges. Indian J Psychol Med 2020;42:22-9. (Corresponding author)
38. Gautam CS, Mahajan SS, Kumar H, Gautam SS Singh H. Romosozumab: Efficacy and safety in postmenopausal women with osteoporosis. JMCC 2020;10:36-40. (Corresponding author).
39. Sharma J, Gutam CS, Singh H, Singh J. “Tafenoquine for Plasmodium vivax malaria: concerns regarding efficacy, safety and published literature”. Sharma J, Gautam CS, Singh H, Singh J. Tafenoquine for Plasmodium vivax malaria: Concerns regarding efficacy & safety. Indian J Med Res. 2021 Jun;154(6):797-805. (Corresponding author).
40. Singh H, Kakkar AK, Chauhan P. Repurposing minocycline for COVID-19 management: mechanisms, opportunities, and challenges. Expert Rev Anti Infect Ther. 2020 Oct;18(10):997-1003.
41. Kaur H, Singh J, Kashyap JR, Rohilla R, Singh H, Jaswal S, Kumar R. Relationship between Statin Associated Muscle Symptoms, Serum Vitamin D and Low Density Lipoprotein-Cholesterol: A Cross-sectional Observational Study. European Endocrinology. 2020;16(2):137–42 DOI: https://doi.org/10.17925/EE.2020.16.2.137. (Corresponding Author).
42. Gautam SS, Gautam CS, Garg VK, Singh H. Combining hydroxychloroquine and minocycline: potential role in moderate to severe COVID-19 infection. Expert Rev Clin Pharmacol. 2020 Nov;13(11):1183-1190.  (Corresponding author)
43. Chauhan P, Kakkar AK, Singh H, Gautam CS. Minocycline for the management of multiple sclerosis: repositioning potential, opportunities, and challenges. Expert Rev Neurother. 2021 Jan;21(1):35-43. (Corresponding author)
44. Singh H, Chauhan P, Kakkar AK. Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead. Eur J Pharmacol. 2021 Jan 5;890:173717. doi: 10.1016/j.ejphar.2020.173717.
45. Manchanda K, Singh J, Bhagat R, Tiwana IK, Singh H. Safety of Pharmacological Options for the Management of COVID-19 in Pregnant Women: An Indian Perspective.2021;32(1):3-17. (Corresponding author)
46.

Singh H, Chauhan P, Singh J, Saurabh, Gautam CS, Kakkar AK. Concomitant use of dexamethasone and tetracyclines: a potential therapeutic option for the management of severe COVID-19 infection? Expert Rev Clin Pharmacol. 2021 Mar;14(3):315-322.

47. Gautam CS, Sharma J, Singla M, Tiwana IK, Singh H. Potential Role of Dexamphetamine in the Treatment of Non-alcoholic Fatty Liver Disease: Hopes and Pitfalls. touchREVIEWS in Endocrinology. 2021;17(1):33–6. (Corresponding author).
48. Chauhan P, Kaur G, Prasad R, Singh H. Pharmacotherapy of schizophrenia: immunological aspects and potential role of immunotherapy. Expert Rev Neurother. 2021 Oct 28:1-13 (Corresponding author).
49. Singh H, Joshi D, Narula S, Singla M, Rohilla R, Singh J. Alternate-day add-on therapy with dapagliflozin in patients with type 2 diabetes mellitus: potential benefits and concerns. Expert Rev Clin Pharmacol. 2022 Feb;15(2):197-203.
50. Goel S, Singh R, Singh V, Singh H, Kumari P, Chopra H, Sharma R, Nepovimova E, Valis M, Kuca K, Emran TB. Metformin: Activation of 5' AMP-activated protein kinase and its emerging potential beyond anti-hyperglycemic action. Front Genet. 2022 Oct 31;13:1022739. doi: 10.3389/fgene.2022.1022739.
51.

Singh H, Sikarwar P, Khurana S, Sharma J. Assessing the Incidence of New-onset Diabetes Mellitus with Statin Use: A Systematic Review of the Systematic Reviews and Meta-analyses. touchREV Endocrinol. 2022 Nov;18(2):96-101. doi: 10.17925/EE.2022.18.2.96.
52. Singh H, Sharma J, Sikarwar P, Kakkar AK. Dipeptidyl peptidase 4 (DPP-4) inhibitors and the risk of lung cancer: current evidence and future directions. Expert Rev Clin Pharmacol. 2023 Jan;16(1):39-47. doi: 10.1080/17512433.2023.2161045.
53. Singh H, Singh J, Bhangu RK, Singla M, Singh J, Javid F. Potential approaches using teneligliptin for the treatment of type 2 diabetes mellitus: current status and future prospects. Expert Rev Clin Pharmacol. 2023 Jan;16(1):49-59. doi: 10.1080/17512433.2023.2163386.
54. Singh H, Arora E, Narula S, Singla M, Otaal A, Sharma J. Finding the most cost-effective option from commonly used Dipeptidyl peptidase-4 inhibitors in India: a systematic study. Expert Rev Endocrinol Metab. 2023 Sep- Nov;18(4):347-354.
55. Rohilla R, Kapoor P, Gupta N and Singh H: Pharmacological options for management of Covid-19: issues concerning ethics and rational medicine use. Int J Pharm Sci & Res 2023; 14(6): 2773-83. doi: 10.13040/IJPSR.0975-8232.14(6).2773-83 (Corresponding author).
56.

Singh H, Rohilla R, Jaswal S, Singla M. Comparison of teneligliptin and other gliptin-based regimens in addressing insulin resistance and glycemic control in type 2 diabetic patients: a cross-sectional study. Expert Rev Endocrinol Metab. 2023 Nov 30:1-7.
57. Singh H, Nim DK, Randhawa AS, Ahluwalia S. Integrating clinical pharmacology and artificial intelligence: potential benefits, challenges, and role of clinical pharmacologists. Expert Rev Clin Pharmacol. 2024 Feb 15:1-11.

 

 

Back